{"entity":{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","aka":[],"tldr":"GI oncologist behind trials of KRAS, HER2, and FGFR-directed therapy in colorectal and bile duct cancer.","summary":"Tanios Bekaii-Saab is Professor of Medicine and Leader of the GI Cancer Program at Mayo Clinic Arizona, part of the Mayo Clinic Comprehensive Cancer Center. A medical oncologist specialising in colorectal and biliary cancer, he leads gastrointestinal cancer research in Arizona and has been an investigator on ANCHOR CRC, MOUNTAINEER and FGFR2 inhibitor trials in cholangiocarcinoma. His papers include the New England Journal of Medicine report of adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C and the ReDOS phase 2 study of regorafenib dose-optimisation in refractory metastatic colorectal cancer. A frequent voice on colorectal cancer treatment sequencing, his work spans KRAS, HER2 and FGFR2 in colorectal, biliary tract and pancreatic cancer.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bekaii-Saab%20T%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Tanios%20Bekaii-Saab"}],"tags":[],"related":[],"cancers":["colorectal","cholangiocarcinoma","pancreatic"],"sections":[],"technologies":[],"targets":["kras","her2","fgfr2"],"drugs":[],"companies":[],"institutions":["mayo-clinic","mayo-clinic-arizona"],"pathways":[],"terms":[],"trials":["mountaineer"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine; Leader, GI Cancer Program, Mayo Clinic Arizona","institutionId":"mayo-clinic","specialisms":["Gastrointestinal oncology","Colorectal cancer","Biliary cancer"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bekaii-Saab%20T%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Tanios%20Bekaii-Saab"}],"papers":[{"title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/nejmoa2212419","doi":"10.1056/nejmoa2212419"},{"title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","journal":"Lancet Oncology","year":2019,"url":"https://doi.org/10.1016/S1470-2045(19)30272-4","doi":"10.1016/S1470-2045(19)30272-4"},{"title":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAPOLI-3+NALIRIFOX+Wainberg+Lancet"}],"orcid":"0000-0001-7721-1699"},"route":"/people/tanios-bekaii-saab/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"institution":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/"},{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","route":"/institutions/mayo-clinic-arizona/"}],"trial":[{"id":"canstem111p","kind":"trial","name":"CanStem111P","route":"/trials/canstem111p/"},{"id":"fight-302","kind":"trial","name":"FIGHT-302","route":"/trials/fight-302/"},{"id":"mountaineer","kind":"trial","name":"MOUNTAINEER","route":"/trials/mountaineer/"}],"paper":[{"id":"paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023","kind":"paper","name":"KRYSTAL-1: adagrasib in advanced solid tumours harbouring a KRAS G12C mutation, including pancreatic cancer","route":"/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/"},{"id":"paper-napoli-3-lancet-2023","kind":"paper","name":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","route":"/key-papers/paper-napoli-3-lancet-2023/"},{"id":"paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)","route":"/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/"}]}}